Merck KGaA (MRK: DE) hailed a year of record growth in 2021.
The German life sciences group announced on Thursday that sales throughout the year increased by 12.3% to 19.7 billion euros ($21.8 billion) compared with the previous year.
All three of Merck’s business sectors, including Healthcare, contributed to this sales growth, while earnings before interest, taxes, depreciation and amortization (EBITDA) rose 20.8% to 5.95 billion euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze